Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) - Stock analysts at Leerink Partnrs decreased their Q3 2025 EPS estimates for Xeris Biopharma in a research report issued to clients and investors on Wednesday, June 4th. Leerink Partnrs analyst R. Ruiz now expects that the company will earn $0.02 per share for the quarter, down from their previous forecast of $0.03. The consensus estimate for Xeris Biopharma's current full-year earnings is ($0.41) per share. Leerink Partnrs also issued estimates for Xeris Biopharma's Q4 2025 earnings at $0.01 EPS and FY2028 earnings at $0.50 EPS.
XERS has been the subject of a number of other research reports. Leerink Partners raised their target price on shares of Xeris Biopharma from $5.00 to $6.00 and gave the company an "outperform" rating in a research report on Friday, March 7th. HC Wainwright reaffirmed a "buy" rating and issued a $8.00 target price (up previously from $6.60) on shares of Xeris Biopharma in a research report on Friday, March 7th. Wall Street Zen downgraded shares of Xeris Biopharma from a "buy" rating to a "hold" rating in a research report on Thursday, May 22nd. Oppenheimer raised their target price on shares of Xeris Biopharma from $6.00 to $7.00 and gave the company an "outperform" rating in a research report on Friday, May 9th. Finally, Craig Hallum raised their target price on shares of Xeris Biopharma from $5.00 to $6.50 and gave the company a "buy" rating in a research report on Friday, March 7th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, Xeris Biopharma has an average rating of "Moderate Buy" and an average price target of $6.25.
Read Our Latest Analysis on Xeris Biopharma
Xeris Biopharma Stock Performance
Xeris Biopharma stock traded up $0.12 during mid-day trading on Friday, reaching $4.58. The company's stock had a trading volume of 1,820,428 shares, compared to its average volume of 1,972,475. The company has a market capitalization of $716.24 million, a price-to-earnings ratio of -10.18 and a beta of 1.10. Xeris Biopharma has a 12 month low of $2.03 and a 12 month high of $6.07. The business's 50 day simple moving average is $4.56 and its 200 day simple moving average is $4.07.
Xeris Biopharma (NASDAQ:XERS - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.01. The company had revenue of $57.80 million for the quarter, compared to the consensus estimate of $57.61 million.
Insider Buying and Selling at Xeris Biopharma
In other Xeris Biopharma news, insider Beth Hecht sold 40,000 shares of the stock in a transaction on Thursday, March 20th. The shares were sold at an average price of $5.43, for a total value of $217,200.00. Following the completion of the sale, the insider now owns 1,353,510 shares in the company, valued at $7,349,559.30. This trade represents a 2.87% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 6.47% of the company's stock.
Institutional Trading of Xeris Biopharma
A number of hedge funds have recently modified their holdings of XERS. Nuveen LLC acquired a new stake in shares of Xeris Biopharma during the 1st quarter worth about $12,240,000. Parkman Healthcare Partners LLC lifted its stake in shares of Xeris Biopharma by 207.8% during the 1st quarter. Parkman Healthcare Partners LLC now owns 1,780,454 shares of the company's stock worth $9,775,000 after buying an additional 1,201,943 shares during the last quarter. Goldman Sachs Group Inc. lifted its stake in shares of Xeris Biopharma by 75.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company's stock worth $15,317,000 after buying an additional 1,199,435 shares during the last quarter. Invesco Ltd. lifted its stake in shares of Xeris Biopharma by 1,387.8% during the 1st quarter. Invesco Ltd. now owns 1,026,838 shares of the company's stock worth $5,637,000 after buying an additional 957,822 shares during the last quarter. Finally, Driehaus Capital Management LLC lifted its stake in shares of Xeris Biopharma by 137.6% during the 1st quarter. Driehaus Capital Management LLC now owns 1,411,540 shares of the company's stock worth $7,749,000 after buying an additional 817,525 shares during the last quarter. Institutional investors and hedge funds own 42.75% of the company's stock.
About Xeris Biopharma
(
Get Free Report)
Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.
Recommended Stories
Before you consider Xeris Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xeris Biopharma wasn't on the list.
While Xeris Biopharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
